Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 4/2011

01-08-2011

What Is the Role of Genetic Testing in Movement Disorders Practice?

Authors: Susanne A. Schneider, Christine Klein

Published in: Current Neurology and Neuroscience Reports | Issue 4/2011

Login to get access

Abstract

Genetic testing holds many promises in movement disorders, but also pitfalls that require careful consideration for meaningful results. These include the primary indication for testing in the first place, concerns regarding the implications of symptomatic, presymptomatic, and susceptibility testing, the mutation frequency in the gene of interest, the general lack of neuroprotective treatment options for neurodegenerative movement disorders, the prognosis of the condition diagnosed, and patient confidentiality concerns. Furthermore, new technical achievements and the available technical expertise, feasibility of specific gene testing, and its coverage through a health insurance carrier should be considered. Guidelines for testing have been established by some disease societies to advise clinicians and in parallel legal regulations are being adjusted at a national and international level. We review these and other critical points and recent developments regarding genetic testing in the field of movement disorders.
Literature
1.
Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008;7:583–90.PubMedCrossRef
2.
Klein C, Lohmann-Hedrich K, Rogaeva E, et al. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol. 2007;6:652–62.PubMedCrossRef
3.
Ensenauer RE, Michels VV, Reinke SS. Genetic testing: practical, ethical, and counseling considerations. Mayo Clin Proc. 2005;80:63–73.PubMedCrossRef
4.
Risch NJ, Bressman SB, Senthil G, et al. Intragenic Cis and Trans modification of genetic susceptibility in DYT1 torsion dystonia. Am J Hum Genet. 2007;80:1188–93.PubMedCrossRef
5.
Schneider SA, Bhatia KP, Hardy J. Complicated recessive dystonia parkinsonism syndromes. Mov Disord. 2009;24:490–9.PubMedCrossRef
6.
Schneider SA, Bhatia KP. Three faces of the same gene: FA2H links neurodegeneration with brain iron accumulation, leukodystrophies, and hereditary spastic paraplegias. Ann Neurol. 2010;68:575–7.PubMedCrossRef
7.
Klein C, Schneider SA, Lang AE: Hereditary parkinsonism: Parkinson disease look-alikes – an algorithm for clinicians to 'PARK' genes and beyond. Mov Disord. 2009;24(14):2042–58.
8.
Schneider SA, Walker RH, Bhatia KP. The Huntington's disease-like syndromes: what to consider in patients with a negative Huntington's disease gene test. Nat Clin Pract Neurol. 2007;3:517–25.PubMedCrossRef
9.
Guidelines for the molecular genetics predictive test in Huntington's disease. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington's Chorea. Neurology. 1994;44:1533–6.
10.
Bressman SB, Sabatti C, Raymond D, et al. The DYT1 phenotype and guidelines for diagnostic testing. Neurology. 2000;54:1746–52.PubMed
11.
Harbo HF, Finsterer J, Baets J, et al. EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington's disease, Parkinson's disease and dystonias. Eur J Neurol. 2009;16:777–85.PubMedCrossRef
12.
Conkie-Rosell A, Abrams L, Finucane B, et al. Recommendations from multi-disciplinary focus groups on cascade testing and genetic counseling for fragile X-associated disorders. J Genet Couns. 2007;16:593–606.CrossRef
13.
Convention for the protection of human rights and dignity of the human being with regard to the application of biology and medicine:convention on human rights and biomedicine. http://​conventions coe int/treaty/en/treaties/html/164 htm. 1997;
14.
•• Borry P, Evers-Kiebooms G, Cornel MC, et al.: Genetic testing in asymptomatic minors: background considerations towards ESHG Recommendations. Eur J Hum Genet. 2009; 17:711–719. This paper is the background document in preparation of the development of the policy recommendations of the Public and Professional Committee of the European Society of Human Genetics. It discusses general considerations regarding genetic testing of minors including the concept of best interest, participation of minors in health care decisions, parents' responsibilities to share genetic information, the role of clinical genetics, and the health care system in communication within the family.PubMedCrossRef
15.
Ross LF, Moon MR. Ethical issues in pediatric genetics. In: Mahowald MB, McJusick VA, Scheuerle AS, et al., editors. Genetics in the clinic: Clinical, ethical, and social implications for primary care. St Louis: Mosby; 2010. p. 153–66.
16.
Nelson RM, Botkijn JR, Kodish ED, et al. Committee on bioethics. Ethical issues with genetic testing in pediatrics. Pediatrics. 2001;107:1451–5.CrossRef
17.
Borry P, Stultiens L, Nys H, et al. Presymptomatic and predictive genetic testing in minors: a systematic review of guidelines and position papers. Clin Genet. 2006;70:374–81.PubMedCrossRef
18.
Borry P, Stultiens L, Goffin T, et al. Minors and informed consent in carrier testing: a survey of European clinical geneticists. J Med Ethics. 2008;34:370–4.PubMedCrossRef
19.
Borry P, Goffin T, Nys H, et al. Predictive genetic testing in minors for adult-onset genetic diseases. Mt Sinai J Med. 2008;75:287–96.PubMedCrossRef
20.
Sermon K, Seneca S, De Rijcke M, et al. PGD in the lab for triplet repeat diseases—myotonic dystrophy, Huntington's disease and Fragile-X syndrome. Mol Cell Endocrinol. 2001;183 Suppl 1:S77–85.PubMedCrossRef
21.
Sermon K, De Rijcke M, Lissens W, et al. Preimplantation genetic diagnosis for Huntington's disease with exclusion testing. Eur J Hum Genet. 2002;10:591–8.PubMedCrossRef
22.
23.
Mandich P, Jacopini G, Di Maria E, et al. Predictive testing for Huntington's disease: ten years' experience in two Italian centres. Ital J Neurol Sci. 1998;19:68–74.PubMedCrossRef
24.
Edgeworth JA, Farmer M, Sicilia A, et al.: Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet. 2011;377(9764):487–93.
25.
Duncan RE, Delatycki MB, Collins SJ, et al. Ethical considerations in presymptomatic testing for variant CJD. J Med Ethics. 2005;31:625–30.PubMedCrossRef
26.
Meiser B, Dunn S. Psychological impact of genetic testing for Huntington's disease: an update of the literature. J Neurol Neurosurg Psychiatry. 2000;69:574–8.PubMedCrossRef
27.
Mastromauro C, Myers RH, Berkman B. Attitudes toward presymptomatic testing in Huntington disease. Am J Med Genet. 1987;26:271–82.PubMedCrossRef
28.
Jacopini GA, D'Amico R, Frontali M, et al. Attitudes of persons at risk and their partners toward predictive testing. Birth Defects Orig Artic Ser. 1992;28:113–7.PubMed
29.
Jacobs H, Latza U, Vieregge A, et al. Attitudes of young patients with Parkinson's disease towards possible presymptomatic and prenatal genetic testing. Genet Couns. 2001;12:55–67.PubMed
30.
Bombard Y, Veenstra G, Friedman JM, et al. Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey. BMJ. 2009;338:b2175.PubMedCrossRef
31.
Tan EK, Lee J, Hunter C, et al. Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. J Neurol Sci. 2007;252:113–20.PubMedCrossRef
32.
Almqvist EW, Bloch M, Brinkman R, et al. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet. 1999;64:1293–304.PubMedCrossRef
33.
Coustasse A, Pekar A, Sikula A, et al. Ethical considerations of genetic presymptomatic testing for Huntington's disease. J Hosp Mark Public Relations. 2009;19:129–41.PubMedCrossRef
34.
Williams JK, Schutte DL, Evers C, et al. Redefinition: coping with normal results from predictive gene testing for neurodegenerative disorders. Res Nurs Health. 2000;23:260–9.PubMedCrossRef
35.
Robins Wahlin TB. To know or not to know: a review of behaviour and suicidal ideation in preclinical Huntington's disease. Patient Educ Couns. 2007;65:279–87.PubMedCrossRef
36.
Craufurd D, Tyler A. Predictive testing for Huntington's disease: protocol of the UK huntington's Prediction Consortium. J Med Genet. 1992;29:915–8.PubMedCrossRef
37.
Rantanen E, Hietala M, Kristoffersson U, et al. What is ideal genetic counselling? A survey of current international guidelines. Eur J Hum Genet. 2008;16:445–52.PubMedCrossRef
38.
Morling N, Allen RW, Carracedo A, et al. Paternity testing commission of the international society of forensic genetics: recommendations on genetic investigations in paternity cases. Forensic Sci Int. 2002;129:148–57.PubMedCrossRef
39.
Budowle B, van Daal A. Extracting evidence from forensic DNA analyses: future molecular biology directions. Biotechniques. 2009;46:339–50.PubMedCrossRef
40.
Godard B, Raeburn S, Pembrey M, et al. Genetic information and testing in insurance and employment: technical, social and ethical issues. Eur J Hum Genet. 2003;11 Suppl 2:S123–42.PubMedCrossRef
41.
42.
Brinkmann TH. Die Zulaessigkeit der Verwertung von genetischen Informationen im deutschen und amerikanischen Versicherungsrecht. Karlsruhe: Verlag Versicherungswirthschaft GmbH; 2006.
43.
Simon J, Knoepffler N, Buyten R. Gendiagnostik und Versicherung - die internationale Lage im Vergleich. Baden Baden: Nomos; 2001.
44.
Nicolas P. Ethical and juridical issues of genetic testing: a review of the international regulation. Crit Rev Oncol Hematol. 2009;69:98–107.PubMedCrossRef
45.
• Ziegler J, Ziegler A: Gendiagnostikgesetz und Versicherung: Anspruch und Wirklichkeit. Zeitschrift für die gesamte Versicherungswissenschaft. 2011;100:29–53. New laws have been enacted to regulate the improper use of genetic information by health and life insurers. However, as the authors elaborate there are legal discrepancies. Examples include the yet incomplete protection against genetic discrimination and, on the other hand, the violation of the right to genetic informational self-determination. Harmonization of legal systems thus appears to be a timely and urgent task.
46.
Präve P. Das Gendiagnostikgesetz aus versicherungsrechtlicher Sicht. Zeitschrift für Versicherungsrecht, Haftungs- und Schadenrecht. 2009;60:857–912.
47.
Netzer C, Klein C, Kohlhase J, et al. New challenges for informed consent through whole genome array testing. J Med Genet. 2009;46:495–6.PubMedCrossRef
48.
Kuhlenbaumer G, Hullmann J, Appenzellerm S: Novel genomic techniques open new avenues in the analysis of monogenic disorders. Hum Mutat. 2011;32(2):144–5.
49.
Boddington P. The ethics and regulation of direct-to-consumer genetic testing. Genome Medicine. 2009;1:71.PubMedCrossRef
50.
•• Tamir S: Direct-to-consumer genetic testing: ethical - legal perspectives and practical considerations. Medical Law Review. 2010; 18:213–238. This recent paper discusses the complexity, implications, limitations, and potentially harmful role of the increasing demand of instantaneous DTC genetic testing. The author compares major companies offering DTC and points out the lacunae of legislative regulations.PubMedCrossRef
51.
Durbin RM, Abecasis GR, Altshuler DL, et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467:1061–73.CrossRef
52.
ACMG Laboratory Practice Committee Working Group. ACMG recommendations for standards for interpretation of sequence variations. Genet Med. 2000;2:302–3.CrossRef
53.
Petrucelli N, Lazebnik N, Huelsman KM, et al. Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2: a survey of genetic counseling practice. Genet Test. 2002;6:107–13.PubMedCrossRef
54.
McInerney-Leo A, Hadley DW, Gwinn-Hardy K, et al. Genetic testing in Parkinson's disease. Mov Disord. 2005;20:1–10.PubMedCrossRef
Metadata
Title
What Is the Role of Genetic Testing in Movement Disorders Practice?
Authors
Susanne A. Schneider
Christine Klein
Publication date
01-08-2011
Publisher
Current Science Inc.
Published in
Current Neurology and Neuroscience Reports / Issue 4/2011
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-011-0200-4

Other articles of this Issue 4/2011

Current Neurology and Neuroscience Reports 4/2011 Go to the issue

Clinical Trial Report

Prolonged Postictal Suppression: A Potential Marker for Higher Risk of SUDEP, a Clue to Mechanism, or Both?

ReviewPaper

An Update on Psychogenic Movement Disorders

ReviewPaper

Biofeedback and Epilepsy

ReviewPaper

Alternative Surgical Approaches in Epilepsy

ReviewPaper

Hormonal Therapy for Epilepsy

ReviewPaper

Antiepileptic Drugs and Neurodevelopment: An Update